FR21C1062I1 - Traitement combiné de tumeurs exprimant la cd38 - Google Patents
Traitement combiné de tumeurs exprimant la cd38Info
- Publication number
- FR21C1062I1 FR21C1062I1 FR21C1062C FR21C1062C FR21C1062I1 FR 21C1062 I1 FR21C1062 I1 FR 21C1062I1 FR 21C1062 C FR21C1062 C FR 21C1062C FR 21C1062 C FR21C1062 C FR 21C1062C FR 21C1062 I1 FR21C1062 I1 FR 21C1062I1
- Authority
- FR
- France
- Prior art keywords
- combination treatment
- expressing tumors
- tumors
- expressing
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84732906P | 2006-09-26 | 2006-09-26 | |
DKPA200601232 | 2006-09-26 | ||
PCT/DK2007/000418 WO2008037257A2 (fr) | 2006-09-26 | 2007-09-26 | Traitement combiné de tumeurs exprimant la cd38 |
Publications (1)
Publication Number | Publication Date |
---|---|
FR21C1062I1 true FR21C1062I1 (fr) | 2022-02-18 |
Family
ID=39156080
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR19C1057C Active FR19C1057I1 (fr) | 2006-09-26 | 2019-10-09 | Traitement combiné de tumeurs exprimant la cd38 |
FR19C1056C Active FR19C1056I1 (fr) | 2006-09-26 | 2019-10-09 | Traitement combiné de tumeurs exprimant la cd38 |
FR19C1055C Active FR19C1055I1 (fr) | 2006-09-26 | 2019-10-09 | Traitement combiné de tumeurs exprimant la cd38 |
FR20C1034C Active FR20C1034I1 (fr) | 2006-09-26 | 2020-07-16 | Traitement combiné de tumeurs exprimant la cd38 |
FR21C1062C Active FR21C1062I1 (fr) | 2006-09-26 | 2021-12-20 | Traitement combiné de tumeurs exprimant la cd38 |
FR21C1063C Active FR21C1063I1 (fr) | 2006-09-26 | 2021-12-20 | Traitement combiné de tumeurs exprimant la cd38 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR19C1057C Active FR19C1057I1 (fr) | 2006-09-26 | 2019-10-09 | Traitement combiné de tumeurs exprimant la cd38 |
FR19C1056C Active FR19C1056I1 (fr) | 2006-09-26 | 2019-10-09 | Traitement combiné de tumeurs exprimant la cd38 |
FR19C1055C Active FR19C1055I1 (fr) | 2006-09-26 | 2019-10-09 | Traitement combiné de tumeurs exprimant la cd38 |
FR20C1034C Active FR20C1034I1 (fr) | 2006-09-26 | 2020-07-16 | Traitement combiné de tumeurs exprimant la cd38 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR21C1063C Active FR21C1063I1 (fr) | 2006-09-26 | 2021-12-20 | Traitement combiné de tumeurs exprimant la cd38 |
Country Status (22)
Country | Link |
---|---|
US (3) | US9040050B2 (fr) |
EP (3) | EP3569245A1 (fr) |
JP (6) | JP5476122B2 (fr) |
AU (2) | AU2007302448C1 (fr) |
CA (1) | CA2664740C (fr) |
CY (5) | CY1121813T1 (fr) |
DK (1) | DK2081595T3 (fr) |
EA (1) | EA034877B1 (fr) |
ES (1) | ES2732278T3 (fr) |
FR (6) | FR19C1057I1 (fr) |
HR (1) | HRP20191115T1 (fr) |
HU (6) | HUE044136T2 (fr) |
IL (2) | IL197727A (fr) |
LT (7) | LT2081595T (fr) |
ME (1) | ME03503B (fr) |
NZ (1) | NZ576122A (fr) |
PL (1) | PL2081595T3 (fr) |
PT (1) | PT2081595T (fr) |
RS (1) | RS59005B1 (fr) |
SI (1) | SI2081595T1 (fr) |
TR (1) | TR201910145T4 (fr) |
WO (1) | WO2008037257A2 (fr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME03528B (fr) * | 2005-03-23 | 2020-04-20 | Genmab As | Anticorps dirigés contre cd38 pour le traitement du myélome multiple |
PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
EP2191840A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan |
EP2191841A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine |
EP2191842A1 (fr) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine |
IN2012DN02826A (fr) * | 2009-10-21 | 2015-07-24 | Immunogen Inc | |
RS59769B1 (sr) | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
RU2595839C2 (ru) * | 2010-09-27 | 2016-08-27 | МорфоСис АГ | Антитело к cd38 и леналидомид или бортезомиб для лечения множественной миеломы и nhl |
UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
ES2792062T3 (es) | 2011-05-09 | 2020-11-06 | Mayo Found Medical Education & Res | Tratamientos contra el cáncer |
WO2013059885A2 (fr) | 2011-10-28 | 2013-05-02 | Cephalon Australia Pty Ltd | Produits de recombinaison de polypeptide et utilisations de ceux-ci |
BR112015006731A2 (pt) | 2012-09-25 | 2017-07-04 | Morphosys Ag | combinações e usos das mesmas |
EP2903610B1 (fr) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Traitements antinéoplasiques |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
RU2723937C2 (ru) * | 2013-03-13 | 2020-06-18 | Санофи | Композиции, включающие антитела к cd38 и карфилзомиб |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
CN110526971B (zh) | 2013-04-29 | 2023-06-30 | 泰华制药澳大利亚公司 | 抗-CD38抗体和与致弱干扰素α-2B的融合体 |
KR20160077155A (ko) * | 2013-10-31 | 2016-07-01 | 사노피 | 인간 암을 치료하기 위한 특이적 항-cd38 항체 |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
UA119352C2 (uk) * | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
EP3154595A4 (fr) * | 2014-06-16 | 2018-01-24 | Mayo Foundation for Medical Education and Research | Traitement de myélomes |
US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
UA122212C2 (uk) | 2014-09-09 | 2020-10-12 | Янссен Байотек, Інк. | Вид комбінованої терапії з застосуванням антитіла до cd38 |
US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
US10544199B2 (en) | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
IL307913A (en) * | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
PL3294769T3 (pl) * | 2015-05-13 | 2021-07-05 | Morphosys Ag | Leczenie szpiczaka mnogiego (mm) |
CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
PE20181323A1 (es) | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
CA2990620A1 (fr) * | 2015-06-24 | 2016-12-29 | Janssen Biotech, Inc. | Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant specifiquement a cd38 |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體-抗體組合物及其製造及使用方法 |
TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
EP3399861A4 (fr) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | Procédés de traitement du cancer par interféron |
AU2017217881B2 (en) | 2016-02-12 | 2022-11-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
WO2017165439A1 (fr) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Procédés d'amélioration de l'indice thérapeutique d'un médicament chimiothérapeutique |
AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
KR20190053203A (ko) | 2016-09-01 | 2019-05-17 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | T-세포 암을 표적화하는 방법 및 조성물 |
EP3506942B1 (fr) | 2016-09-01 | 2022-11-16 | Mayo Foundation for Medical Education and Research | Compositions d'agents de liaison et de porteuses pd-l1 pour le traitement de cancers |
US11311631B2 (en) | 2016-09-06 | 2022-04-26 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
CA3035655A1 (fr) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Procedes de traitement du cancer exprimant pd-l1 |
WO2018048815A1 (fr) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Méthodes de traitement d'un cancer du sein triple-négatif à l'aide de compositions d'anticorps et de protéines porteuses |
WO2018098348A1 (fr) * | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Combinaisons pharmaceutiques comprenant un inhibiteur d'histone désacétylase et un inhibiteur de cd38 et leurs méthodes d'utilisation |
DK3581190T3 (da) | 2016-12-09 | 2021-06-07 | Onk Therapeutics Ltd | Manipulerede naturlige dræberceller og anvendelser deraf |
KR102631281B1 (ko) * | 2017-08-10 | 2024-01-30 | 그리폴스 다이어그노스틱 솔루션즈 인크. | 재조합 인간 cd38-세포외 도메인을 포함하는 조성물, 방법 및/또는 키트 |
WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
JP6648171B2 (ja) * | 2018-02-02 | 2020-02-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物 |
JOP20200292A1 (ar) * | 2018-05-16 | 2020-11-15 | Stichting Vumc | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان |
WO2020012038A1 (fr) | 2018-07-13 | 2020-01-16 | Genmab A/S | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
BR112020026432A2 (pt) | 2018-07-13 | 2021-03-23 | Genmab A/S | variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso |
WO2020072840A1 (fr) * | 2018-10-03 | 2020-04-09 | Prescient Pharma Llc | Compositions et méthodes pour isoler des cellules circulantes |
TW202102541A (zh) | 2019-03-15 | 2021-01-16 | 德商莫菲西斯公司 | 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 |
TW202112373A (zh) | 2019-06-10 | 2021-04-01 | 日商武田藥品工業股份有限公司 | 使用抗cd38抗體之組合療法 |
GB201916150D0 (en) | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
CN112876563B (zh) | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技(成都)有限公司 | 药物组合物及其制备方法和应用 |
JP6853392B2 (ja) * | 2020-01-15 | 2021-03-31 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物 |
US20230272105A1 (en) | 2020-01-16 | 2023-08-31 | Genmab A/S | Formulations of cd38 antibodies and uses thereof |
JP2023516195A (ja) | 2020-02-26 | 2023-04-18 | バイオグラフ 55,インク. | C19 c38二特異性抗体 |
EP4121112A4 (fr) | 2020-05-08 | 2023-11-15 | The University Of Southern California | Conjugués anticorps-médicament spécifiques au site par adp-ribosyl cyclases |
US20240101695A1 (en) * | 2020-09-01 | 2024-03-28 | The Regents Of The University Of California | Immunoglobulin e antibody compositions and methods of use |
EP4277930A1 (fr) | 2021-01-14 | 2023-11-22 | MorphoSys AG | Anticorps anti-cd38 et leurs utilisations |
TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗cd38抗體 |
TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
WO1989008114A1 (fr) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Procede de clonage par immunoselection rapide |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
CA2109602C (fr) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methodes de production de membres de paires de liaison specifiques |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2087272C (fr) | 1990-07-13 | 2005-10-11 | Brian Seed | Antigene de surface des lymphocytes cd53 et son utilisation |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
DE69233697T2 (de) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Verfahren zur Entwicklung von bindenden Mikroproteinen |
EP0580737B1 (fr) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Banques de recepteurs heterodimeres utilisant des phagemides |
AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
WO1994017184A1 (fr) | 1993-01-29 | 1994-08-04 | Schering Corporation | Modulation de la reponse physiologique de lymphocytes par les molecules cd38 ou leurs anti-corps |
JP3801196B2 (ja) | 1993-03-09 | 2006-07-26 | ジェンザイム・コーポレイション | 乳からの対象化合物の単離 |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
JP4233608B2 (ja) | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
ES2191827T3 (es) | 1996-10-17 | 2003-09-16 | Immunomedics Inc | Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular. |
WO2000006194A2 (fr) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion de cellules responsables du rejet d'une greffe induit par des anticorps |
EP0975674B1 (fr) | 1997-05-02 | 2005-08-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Immunotoxines, comprenant une proteine onc, dirigees contre des cellules malignes |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6719977B1 (en) | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
WO1999050392A1 (fr) | 1998-03-31 | 1999-10-07 | Geron Corporation | Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase |
AU770718B2 (en) * | 1998-06-05 | 2004-02-26 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to CD38 to treat multiple myeloma |
CN100531798C (zh) * | 1998-08-11 | 2009-08-26 | 拜奥根Idec公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
US20050037969A1 (en) | 1999-05-14 | 2005-02-17 | Arbor Vita Corporation | Molecular interactions in hematopoietic cells |
JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | HER2/neuに対するヒトモノクローナル抗体 |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
EP1174440A1 (fr) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display" |
US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
CA2424643A1 (fr) | 2000-10-17 | 2002-04-25 | Trudeau Institute, Inc. | Chimiotaxie modulee du gene cd38 |
WO2002042468A2 (fr) | 2000-11-27 | 2002-05-30 | Geron Corporation | Vecteurs de glycosyltransferase pour traitement du cancer |
KR100857943B1 (ko) | 2000-11-30 | 2008-09-09 | 메다렉스, 인코포레이티드 | 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
IL159225A0 (en) | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
US20040019915A1 (en) | 2002-04-01 | 2004-01-29 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
EP1393720A1 (fr) | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicules encapsulant des corticosteroides pour le traitement du cancer |
NZ581541A (en) | 2002-10-17 | 2011-07-29 | Genmab As | Human monoclonal antibodies against CD20 |
WO2004045512A2 (fr) | 2002-11-15 | 2004-06-03 | Genmab A/S | Anticorps monoclonaux humains contre cd25 |
ATE527278T1 (de) | 2002-12-16 | 2011-10-15 | Genmab As | Humane monoklonale antikörper gegen interleukin 8 (il-8) |
US7109304B2 (en) * | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
US20070031406A1 (en) | 2003-10-22 | 2007-02-08 | Zand Martin S | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
KR101128777B1 (ko) * | 2003-11-04 | 2012-04-13 | 조마 테크놀로지 리미티드 | 다발성 골수종을 치료하기 위한 길항제 항-cd40단클론성 항체의 용도 |
WO2005046593A2 (fr) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies |
SI2511297T1 (sl) * | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
ES2541489T3 (es) | 2004-02-06 | 2015-07-21 | Morphosys Ag | Anticuerpos humanos anti-CD38 y usos para ellos |
US20050266008A1 (en) | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
CN100416371C (zh) * | 2004-04-21 | 2008-09-03 | 大日本印刷株式会社 | 彩色滤光片和具备该彩色滤光片的液晶显示装置 |
US20060019303A1 (en) | 2004-07-23 | 2006-01-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method to identify and analyze genes having modified expression in stimulated T cells |
ME03528B (fr) | 2005-03-23 | 2020-04-20 | Genmab As | Anticorps dirigés contre cd38 pour le traitement du myélome multiple |
US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
-
2007
- 2007-09-26 PL PL07817816T patent/PL2081595T3/pl unknown
- 2007-09-26 PT PT07817816T patent/PT2081595T/pt unknown
- 2007-09-26 DK DK07817816.7T patent/DK2081595T3/da active
- 2007-09-26 ES ES07817816T patent/ES2732278T3/es active Active
- 2007-09-26 CA CA2664740A patent/CA2664740C/fr active Active
- 2007-09-26 AU AU2007302448A patent/AU2007302448C1/en active Active
- 2007-09-26 EP EP19168122.0A patent/EP3569245A1/fr active Pending
- 2007-09-26 NZ NZ576122A patent/NZ576122A/xx unknown
- 2007-09-26 EA EA200970317A patent/EA034877B1/ru active Protection Beyond IP Right Term
- 2007-09-26 TR TR2019/10145T patent/TR201910145T4/tr unknown
- 2007-09-26 LT LTEP07817816.7T patent/LT2081595T/lt unknown
- 2007-09-26 JP JP2009529534A patent/JP5476122B2/ja active Active
- 2007-09-26 EP EP07817816.7A patent/EP2081595B1/fr active Active
- 2007-09-26 HU HUE07817816A patent/HUE044136T2/hu unknown
- 2007-09-26 US US12/442,808 patent/US9040050B2/en active Active
- 2007-09-26 EP EP20174826.6A patent/EP3753576A1/fr active Pending
- 2007-09-26 RS RS20190880A patent/RS59005B1/sr unknown
- 2007-09-26 SI SI200732115T patent/SI2081595T1/sl unknown
- 2007-09-26 ME MEP-2019-194A patent/ME03503B/fr unknown
- 2007-09-26 WO PCT/DK2007/000418 patent/WO2008037257A2/fr active Application Filing
-
2009
- 2009-03-19 IL IL197727A patent/IL197727A/en active IP Right Grant
-
2013
- 2013-04-09 AU AU2013203186A patent/AU2013203186C1/en active Active
-
2014
- 2014-02-07 JP JP2014021875A patent/JP2014141492A/ja active Pending
- 2014-12-10 US US14/566,279 patent/US20150231235A1/en not_active Abandoned
-
2016
- 2016-06-03 JP JP2016111656A patent/JP6607825B2/ja active Active
- 2016-10-06 IL IL248204A patent/IL248204A0/en unknown
-
2018
- 2018-08-24 JP JP2018157054A patent/JP6907165B2/ja active Active
-
2019
- 2019-06-18 HR HRP20191115TT patent/HRP20191115T1/hr unknown
- 2019-07-09 CY CY20191100718T patent/CY1121813T1/el unknown
- 2019-09-12 US US16/569,162 patent/US20200114000A1/en not_active Abandoned
- 2019-10-04 LT LTPA2019514 patent/LTPA2019514I1/lt unknown
- 2019-10-04 LT LTPA2019516 patent/LTPA2019516I1/lt unknown
- 2019-10-04 LT LTPA2019515 patent/LTPA2019515I1/lt unknown
- 2019-10-09 FR FR19C1057C patent/FR19C1057I1/fr active Active
- 2019-10-09 FR FR19C1056C patent/FR19C1056I1/fr active Active
- 2019-10-09 FR FR19C1055C patent/FR19C1055I1/fr active Active
- 2019-10-10 CY CY2019035C patent/CY2019035I2/el unknown
- 2019-10-10 CY CY2019036C patent/CY2019036I1/el unknown
- 2019-10-10 HU HUS1900045 patent/HUS1900045I1/hu unknown
- 2019-10-10 CY CY2019037C patent/CY2019037I2/el unknown
- 2019-10-10 HU HUS1900044 patent/HUS1900044I1/hu unknown
- 2019-10-10 HU HUS1900043 patent/HUS1900043I1/hu unknown
-
2020
- 2020-07-03 CY CY2020016C patent/CY2020016I1/el unknown
- 2020-07-10 LT LTPA2020520C patent/LTPA2020520I1/lt unknown
- 2020-07-16 FR FR20C1034C patent/FR20C1034I1/fr active Active
-
2021
- 2021-05-12 JP JP2021080739A patent/JP2021119198A/ja active Pending
- 2021-12-17 HU HUS2100056C patent/HUS2100056I1/hu unknown
- 2021-12-17 HU HUS2100057C patent/HUS2100057I1/hu unknown
- 2021-12-20 FR FR21C1062C patent/FR21C1062I1/fr active Active
- 2021-12-20 LT LTPA2021015C patent/LTPA2021015I1/lt unknown
- 2021-12-20 FR FR21C1063C patent/FR21C1063I1/fr active Active
- 2021-12-20 LT LTPA2021014C patent/LTPA2021014I1/lt unknown
-
2023
- 2023-06-29 JP JP2023107054A patent/JP2023120436A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1062I1 (fr) | Traitement combiné de tumeurs exprimant la cd38 | |
BRPI0821779A2 (pt) | tratamento terapêutico de câncer | |
LTC2787345I2 (lt) | Fabri ligos gydymo priemonės | |
BRPI0821660A2 (pt) | Combinações de agentes terapêuticos para tratamento de câncer | |
BRPI0811265A2 (pt) | Tratamento de sinucleinopatias | |
BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
BRPI0921482A2 (pt) | tratamento de leucemia linfoblástica aguda | |
EP2049139A4 (fr) | Traitement de tumeurs exprimant ras | |
BRPI0814624A2 (pt) | Tratamento de doença neurodegenerativa progresiva com ibudilaste | |
SMAP200900085A (it) | 3-imidazolil-indoli per il trattamento di malattieproliferative | |
BRPI0912683A2 (pt) | tratamento de tumores metastáticos | |
ATE434620T1 (de) | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen | |
IL197315A0 (en) | Treatment of cancer | |
DK2056842T3 (da) | Modificeret galactosylceramid til behandling af cancerøse sygdomme | |
DE602007006594D1 (de) | Endoskop-Behandlungsinstrument | |
BRPI0815551A2 (pt) | Tratamento através de hucbc de doença beta-amiloide | |
FR2901405B1 (fr) | Appareils de traitement | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
MA28901B1 (fr) | Methode de traitement de cancers | |
GB0700972D0 (en) | Treatment of inflammatory disease | |
BRPI0715728A2 (pt) | tratamento de distérbio cartilaginosos | |
LTC2066352I2 (lt) | Išsėtinės sklerozės (MS) gydymas kampatu-1H | |
FI20095600A (fi) | Koostumus ihosairauksien hoitoa varten | |
FR2884647B1 (fr) | Traitement de plaques de semi-conducteurs | |
FR2897533B1 (fr) | Agent oxydant pour le traitement des cheveux |